Brolucizumab

Trade Name: 
Beovu
Manufacturer/Distributor: 
Novartis Pharmaceuticals Canada Inc.
Classification: 
Antineovascularisation agent
ATC Class: 
S01LA06 - brolucizumab
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2020/03/12
Date Marketed in Canada (yyyy/mm/dd): 
2020/05/15
Presentation: 
Prefilled syringe: 6 mg/0.05 mL. DIN 02496976
Comments: 
Treatment of wet age-related macular degeneration (intravitreal injection).